Reuters: FDA Cuts Halt Years Of Reviews Of New Meds

Reuters reports:

The Trump administration’s mass firings at the FDA have removed employees critical to reviewing new medicines, setting back years of effort to bring promising treatments to patients more quickly, former and current FDA sources told Reuters. The FDA is slated to lose 3,500 employees under HHS Sec. Robert F. Kennedy Jr.’s massive restructuring of U.S. health agencies that is part ofETrump’s wider campaign to dramatically slash the federal workforce.

The firings this week also include all staff responsible for managing records – such as new product applications – at FDA divisions that oversee biotechnology therapies, medical devices, veterinary medicine and tobacco products, three sources said. The office that arranges travel for FDA inspectors who ensure factory production lines are meeting safety standards also was cut, three sources said.

Read the full article.